ISO 15189 accreditation provides a solid framework for quality and technical competence, thereby significantly improving laboratory patient care by establishing comprehensive standards that medical laboratories should meet. Navigate BioPharma Services, Inc.’s recent accreditation by the College of
Artificial Intelligence (AI) has the potential to revolutionize drug discovery and development, offering numerous advantages that could transform current practices in the biopharmaceutical industry. By merging Accenture's advanced capabilities in AI scaling with the innovative ITO™ platform
RTI Surgical recently unveiled a $15 million expansion of its Class III medical device facility in Alachua, Florida, marking a significant milestone in its commitment to advancing tissue engineering. This extensive overhaul includes the addition of a 5,000 square-foot clean room, drastically
Quantum dots, the nanoscale semiconductor particles that exhibit quantum mechanical phenomena, have emerged as a revolutionary tool in biotechnology. Due to their unique optical and electronic properties, quantum dots are being integrated into various applications, enhancing the capabilities of
Lonza has bolstered its presence in the field of antibody-drug conjugates (ADC) by extending its manufacturing collaboration with a renowned biopharma company. This strategic move involves the expansion of its bioconjugation operations at the Ibex Biopark located in Visp, Switzerland. Under this
Roche's recent decision to return the rights to UCB’s anti-tau antibody bepranemab comes after a four-year investment in the Alzheimer's disease drug candidate, which was initially valued at up to $2 billion in milestones. This strategic move happens just before the release of phase 2a data for the
The modern biopharmaceutical industry is witnessing a significant transformation, thanks to the integration of artificial intelligence (AI) tools in early drug discovery. AI’s capabilities in managing and analyzing vast amounts of data generated from cell-based preclinical models through imaging
Charles River Laboratories has taken a significant stride in the realm of biopharmaceutical research by launching the Retrogenix Non-Human Protein Library. This innovation is particularly designed to help clients assess the off-target interactions of their therapeutics with non-human proteins. The
Are Biopharma Companies Ready for Today's Regulatory Challenges? The biopharmaceutical sector is rapidly evolving, with companies constantly innovating to develop new treatments for a variety of diseases. However, navigating the regulatory landscape remains a significant challenge. Stricter
RNA editing has long been a topic of fascination within the field of genetic research. Recent advancements by Wave Life Sciences have transformed this curiosity into a real-world application, with their trials showing promising results for treating alpha-1 antitrypsin deficiency (AATD). This
ITCurated uses cookies to personalize your experience on our website. By continuing to use this site, you agree to our Cookie Policy